These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38716804)

  • 1. Evaluating the utility of
    Nakasone ES; Zemla TJ; Yu M; Lin SY; Ou FS; Carter K; Innocenti F; Saltz L; Grady WM; Cohen SA
    Epigenetics; 2024 Dec; 19(1):2349980. PubMed ID: 38716804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
    Symonds L; Yu M; Zhang Y; Ou FS; Zemla TJ; Carter K; Bertagnolli M; Innocenti F; Bosch LJ; Meijer GA; Carvalho B; Grady WM; Cohen SA
    Epigenetics; 2022 Dec; 17(12):1715-1725. PubMed ID: 35412430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
    Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
    Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-assessing
    Vedeld HM; Nesbakken A; Lothe RA; Lind GE
    Clin Epigenetics; 2018; 10():70. PubMed ID: 29854011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
    Nie C; Han X; Wei R; Leonteva A; Hong J; Du X; Wang J; Zhu L; Zhao Y; Xue Y; Zhou H; Tian W
    BMC Cancer; 2021 May; 21(1):551. PubMed ID: 33992091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.
    Vedeld HM; Andresen K; Eilertsen IA; Nesbakken A; Seruca R; Gladhaug IP; Thiis-Evensen E; Rognum TO; Boberg KM; Lind GE
    Int J Cancer; 2015 Feb; 136(4):844-53. PubMed ID: 24948044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
    Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
    Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.
    Draht MX; Smits KM; Tournier B; Jooste V; Chapusot C; Carvalho B; Cleven AH; Derks S; Wouters KA; Belt EJ; Stockmann HB; Bril H; Weijenberg MP; van den Brandt PA; de Bruïne AP; Herman JG; Meijer GA; Piard F; Melotte V; van Engeland M
    Mol Oncol; 2014 May; 8(3):679-88. PubMed ID: 24560444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
    Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
    Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
    Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
    PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX9 expression predicts relapse of stage II colon cancer patients.
    Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic and epigenomic integration identifies a prognostic signature in colon cancer.
    Yi JM; Dhir M; Van Neste L; Downing SR; Jeschke J; Glöckner SC; de Freitas Calmon M; Hooker CM; Funes JM; Boshoff C; Smits KM; van Engeland M; Weijenberg MP; Iacobuzio-Donahue CA; Herman JG; Schuebel KE; Baylin SB; Ahuja N
    Clin Cancer Res; 2011 Mar; 17(6):1535-45. PubMed ID: 21278247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
    Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
    Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
    Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
    J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.